Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study

Autor: Claudio Borghi, Arrigo F G Cicero, Emanuela Berardi, Crescenzio Bentivenga, Eugenio Roberto Cosentino, Matteo Landolfo, Virna Bui, Rinaldo Miceli, Luca Spinardi, Daniela Degli Esposti
Přispěvatelé: Cosentino ER, Landolfo M, Bentivenga C, Spinardi L, Esposti DD, Cicero AF, Miceli R, Bui V, Berardi E, Borghi C
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Vital capacity
lcsh:Diseases of the circulatory (Cardiovascular) system
Time Factors
Comorbidity
030204 cardiovascular system & hematology
Quinolones
Pulmonary Disease
Chronic Obstructive
0302 clinical medicine
Elderly
Risk Factors
Indacaterol/glycopirronium
030212 general & internal medicine
Lung
Aged
80 and over
COPD
education.field_of_study
Ejection fraction
medicine.diagnostic_test
Chronic obstructive pulmonary disease
Middle Aged
Bronchodilator Agents
Drug Combinations
Treatment Outcome
Italy
Indans
Cardiology
Female
Cardiology and Cardiovascular Medicine
medicine.drug
Research Article
Spirometry
medicine.medical_specialty
Heart Ventricles
Population
Heart failure
Muscarinic Antagonists
Patient Readmission
03 medical and health sciences
FEV1/FVC ratio
Internal medicine
medicine
Humans
education
Adrenergic beta-2 Receptor Agonists
Aged
Retrospective Studies
business.industry
Recovery of Function
medicine.disease
Glycopyrrolate
lcsh:RC666-701
Indacaterol
business
Zdroj: BMC Cardiovascular Disorders, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Cardiovascular Disorders
ISSN: 1471-2261
DOI: 10.1186/s12872-018-0986-y
Popis: BACKGROUND: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) often coexist. Moreover, elderly patients suffering from HF have a higher incidence of COPD, which further complicates their clinical condition. Indacaterol/glycopirronium has shown benefits in the treatment of COPD, with few cardiologic adverse effects. We evaluated the safety and efficacy of this therapy in patients with history of HF. METHODS: We enrolled 56 patients with a history of HF (New York Heart Association [NYHA] classes II and III) and stable COPD. We evaluated blood samples, clinical assessment, echocardiograms and basal spirometry at baseline and after 6 months of therapy with indacaterol/glycopirronium. In addition, the number of re-hospitalizations during the treatment period was evaluated. RESULTS: The treatment was well tolerated. Brain natriuretic peptide (BNP) levels were significantly reduced compared with baseline (p
Databáze: OpenAIRE
Externí odkaz: